May 2003 in “Journal of Investigative Dermatology” The meeting covered advances in understanding hair growth, causes of hair loss, and potential treatments.
July 1996 in “Annals of Internal Medicine” Long-term high-dose fluconazole can cause reversible hair loss.
July 1996 in “Annals of Internal Medicine” In 1995, international medical graduates did better than U.S. graduates on a medical exam.
July 1996 in “Annals of Internal Medicine” International medical graduates scored higher than U.S. graduates on a medical exam.
March 2005 in “Journal of The American Academy of Dermatology” Herbal extract improves hair growth in female pattern baldness.
10 citations
,
July 2022 in “Journal of Medicinal Chemistry” Adding a second method to PROTACs could improve cancer treatment.
9 citations
,
February 2002 in “PubMed” A new gene mutation causes hereditary coproporphyria with reduced enzyme activity.
9 citations
,
February 2024 in “mBio” Biliverdin IXβ and IXδ help Pseudomonas aeruginosa adapt to chronic infections.
November 2021 in “International Journal of Trichology” Low PON1 levels may indicate and predict the severity of hair loss.
February 2026 in “Advanced Science” Targeting the p300/AR axis may help treat polycystic ovary syndrome.
1 citations
,
January 2010 Finasteride is mainly broken down by the enzyme CYP3A4, affecting its levels in the body.
March 2016 in “West Indian medical journal” There is no significant link between alopecia areata and the PON1 enzyme polymorphisms studied.
124 citations
,
January 1996 in “Dermatology” 5 alpha-reductase inhibitors, like finasteride, are used to treat conditions like prostate issues and skin disorders.
20 citations
,
March 2017 in “Reproductive Biology and Endocrinology” Women with PCOS have higher 5α-reductase activity, which may be linked to insulin resistance.
354 citations
,
August 1991 in “Molecular Endocrinology” Human adrenals and gonads have a unique enzyme for steroid hormone production.
8 citations
,
March 2012 in “Mass spectrometry letters” The S9 fraction with GC-IDMS is effective for measuring 5α-reductase activity.
2 citations
,
November 2017 in “Gynecological Endocrinology” The enzyme myo-inositol oxygenase is not linked to the cause of polycystic ovarian syndrome.
64 citations
,
July 2016 in “Cold Spring Harbor Perspectives in Medicine” The p53 protein has complex, sometimes contradictory functions, including tumor suppression and promoting cell survival.
45 citations
,
August 2010 in “Hormone Molecular Biology and Clinical Investigation” Type 3 5α-reductase is more common and finasteride and dutasteride strongly inhibit it.
6 citations
,
March 2003 in “Archiv Der Pharmazie” Scientists made new substances that can block an enzyme linked to prostate issues and hair loss, with potential for creating a new treatment.
14 citations
,
April 2024 in “The Journal of Steroid Biochemistry and Molecular Biology” 5α-reductases increase epitestosterone's effect on androgen receptors.
26 citations
,
January 1992 in “Carcinogenesis” TPA strongly increases ODC activity in certain skin cells, potentially aiding tumor growth.
June 2022 in “Pflügers Archiv - European Journal of Physiology” The enzyme sEH is important for hair growth and its inhibition could help treat hair loss.
December 2004 in “SUNScholar (Stellenbosch University)” Certain genetic markers can indicate a person's risk of developing prostate cancer.
3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
16 citations
,
October 2009 in “Xenobiotica” The tested hair dye ingredients do not form harmful oxidized metabolites in the liver.
1 citations
,
August 2019 in “Journal of Investigative Dermatology” PRDX5 enzyme may contribute to alopecia areata by affecting oxidative stress and autoimmunity.
16 citations
,
December 2018 in “Skin pharmacology and physiology” People with Alopecia Areata have higher oxidative stress and different enzyme activities compared to healthy individuals.
56 citations
,
November 2007 in “Molecular and cellular endocrinology” Two enzymes regulate androgen receptor activity, affecting treatments for androgen insufficiency and benign prostatic hyperplasia.
Newly designed proteins can effectively degrade specific proteins in cells, offering a promising alternative for targeted protein degradation.